Hohl Benjamin
Enliven Therapeutics, Inc. · CHIEF FINANCIAL OFFICER
Hohl Benjamin is listed in filings as CHIEF FINANCIAL OFFICER at Enliven Therapeutics, Inc.. This profile follows SEC Form 4 activity through Mar 10, 2026, including sale activity. Recent filings connect the profile to Enliven Therapeutics, Inc. (ELVN). The current snapshot covers public activity from Jul 1, 2024 to Mar 10, 2026. Reported amounts are shown as $295.8K to $32.2K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.
Latest Trades
| Company | Value | Action | Price | Last Price |
|---|---|---|---|---|
| $296k10k shares | SellMar 6, 2026 | $29.58 | $53.20 |